CTU: A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleDB-1311-O-1001
StatusActive
Effective start/end date11/10/23 → 28/07/28